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The metabolism of cancer cells differs from that of their normal counterparts in a
spectrum of attributes, including imbalances in diverse metabolic arms and pathways,
metabolic plasticity and extent of adaptive responses, levels, and activities of metabolic
enzymes and their upstream regulators and abnormal fluxes of metabolic intermediates
and products. These attributes endow cancer cells with the ability to survive stressors
of the tumor microenvironment and enable them to landscape and exploit the host
terrain, thereby facilitating cancer progression and therapy resistance. Understanding
the molecular and physiological principles of cancer metabolism is one of the key
prerequisites for the development of better anticancer treatments. Therefore, various
aspects of cancer metabolism were addressed at the 5th annual meeting of the
International Society of Cancer Metabolism (ISCaM) in Bratislava, Slovakia, on October
17–20, 2018. The meeting presentations and discussions were traditionally focused on
mechanistic, translational, and clinical characteristics of metabolism and pH control in
cancer, at the level of molecular pathways, cells, tissues, and organisms. In order to
reflect major healthcare challenges of the current era, ISCaM has extended its scope to
metabolic disorders contributing to cancer, as well as to opportunities for their prevention,
intervention, and therapeutic targeting.
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INTRODUCTION
Research on cancer metabolism attracts an increasing interest,
not only because of efforts to better understand principles
of cancer progression but equally because of the need to
bring new ideas and strategies for more effective anticancer
therapies. Due to the enormous metabolic plasticity of cancer
cells responding and adapting to signals from intracellular
and extracellular milieu, this research field is very complex
and rapidly evolving. To address challenges of this dynamic
research area, the International Society of Cancer Metabolism
(ISCaM) was founded in 2014 as a logical expansion of the
International Society for Proton Dynamics in Cancer (ISPDC)
that operated from 2009 to 2014. ISCaM’s scope is to foster
communication and collaboration between scientists engaged
in research of metabolism, acidity, proton dynamics, and
microenvironment in cancer (1–4). On October 17–20th 2018,
ISCaM hold its 5th annual meeting in Bratislava, Slovakia. With
a focus on “Metabolic Adaptations and Targets in Cancer,”
this symposium brought together fundamental researchers and
clinicians, scientists of international reputation and young
investigators and ISCaM members and the international
scientific community to exchange the most recent knowledge
related to cancer metabolism. The meeting consisted of two
keynote lectures and seven sessions with oral presentations by
both senior speakers and junior researchers. The talks were
accompanied by informative poster sessions. As an expression
of high mutual trust among ISCaM members and other
participants, many presentations included entirely new and
unpublished data that underlined the meeting quality and the
ISCaM value.
During the opening lecture, Adrian L. Harris (University
of Oxford, UK) reported on new targetable aspects of cancer
metabolism. He focused on mechanisms of cellular adaptation
to glutamine deficiency, which is one of the key amino acids in
cancer metabolism, and described a new pathway of metabolic
reprogramming and regulating amino acid uptake in conditions
of hypoxia-associated low glutamine.
METABOLIC DISORDERS AND CANCER
Modern society generates a stressful and obesogenic environment
promoting the development of metabolic disorders that
contribute to many chronic diseases, including cancer. In the
initial talk of this session, Stephan Herzig (Helmholtz Center
Munich, Germany) explained the role of lipid metabolism
in metabolic dysfunction-related cancer. He emphasized that
obesity-associated complications do not only increase tumor
risk but also promote metastatic tumor recurrence, thereby
imposing a major threat on affected patients. In turn, end-
stage tumor diseases have a significant impact on systemic
metabolism, in particular causing body wasting, i.e., cachexia.
He discussed the latest findings on key events and alterations of
lipid metabolism relevant for both obesity-triggered metastasis
formation and cancer cachexia, including their therapeutic
aspects. Jozef Ukropec (Biomedical Research Center SAS
Bratislava, Slovakia) then briefly reviewed data on the metabolic
and functional flexibility of the adipose tissue, which largely
determines the metabolic health of humans living in the
obesogenic environment. Next, he described the skeletal muscle
as an endocrine organ providing a spectrum of bioactive
substances to orchestrate the whole-body adaptive response
to exercise in recently finalized intervention studies. He also
presented the design of a currently ongoing study aimed at
investigating benefits of regular exercise in testicular germ
cell cancer survivors. Elisabeth Wyart (University of Torino,
Italy) focused on cachexia, which is a multi-organ wasting
syndrome characterized by irreversible skeletal muscle atrophy
that dramatically increases both morbidity and mortality
in various diseases. Despite its high prevalence in cancer
patients, the mechanism of cancer-induced cachexia remains
unclear. So far, unpublished findings obtained by investigating
cachectic mice bearing CT26-colon cancer suggest striking
alterations in certain regulators of metabolism. Sofia Avnet
(Rizzoli Orthopedic Institute, Italy) provided a thorough
overview of the complex relationships between systemic/local
acidosis and insulin resistance/signaling. Insulin influences
acidosis by promoting glycolysis and, in turn, acidosis lowers
insulin binding to its receptor, inhibits glycolysis, inhibits the
recycling of glucose transporters and reduces insulin secretion by
pancreatic β-cells via transforming growth factor β. Insulin also
affects ion/proton transporters and pH sensors, and resulting
acidosis may enhance insulin resistance through the NF-κB-
driven inflammatory pathway. Eduardo Maldonado (Medical
University of South Carolina, USA) presented the current view
on the modulation of mitochondrial metabolism by statins in
cancer cells, and suggested that it is not mediated by changes
in cholesterol content and does not affect glycolysis. Overall,
insights on the relationships between metabolic disorders and
cancer provided in this session support the importance of
continuing investigations on this topic, which is highly relevant
for improving the lifestyle and healthcare of human populations.
GENETIC, EPIGENETIC, AND
TRANSCRIPTIONAL ELEMENTS OF
CANCER METABOLISM
In this session, the first presentation by Carlos Sebastian
(Candiolo Cancer Institute, Italy) focused on the epigenetic
control of tumor transformation in the intestinal tract. In APCmin
mice, a model prone to intestinal and mammary cancer due to
a non-sense mutation in an allele of the adenomatous polyposis
coli (APC) gene, loss of NAD+-dependent histone deacetylase
Sirtuin 6 (SIRT6) resulted in histone hyperacetylation, increased
the abundance of intestinal stem cells (ISCs) and enhanced the
tumor-initiating potential. Due to high pyruvate dehydrogenase
kinase (PDK) activity, ISCs were highly glycolytic and had low
ROS production, supporting stemness. After transformation,
they were proposed to be at the origin of a Warburg-
phenotype lineage of cancer cells in established intestinal tumors.
Relationships between cancer cell metabolism and epigenetics
were further highlighted by Thomas Grunt (Medical University
of Vienna, Austria), who proposed systems biology as the
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best approach to decipher and target these networks. For
example, he showed that fatty acid synthase (FASN) not only
controls lipogenesis, but also the cell membrane structure, hence
signaling, and epigenetics. Similar to FASN, other enzymes, such
as the acetyl-CoA carboxylase ACC1/ACC2 system, are at the
crossroad between several metabolic and functional pathways in
cancer cells. Precisely identifying these nodal points may be used
for future co-targeting anticancer strategies.
METABOLIC PLASTICITY IN METASTATIC
CASCADE
Metastasis remains a factor of poor prognosis for cancer patients
and themain cause of death by cancer for which there is currently
no specific treatment. In this session, speakers highlighted
the key role of metabolic plasticity in controlling metastatic
dissemination from the primary tumor to colonization of
distant organs. Pierre Sonveaux (UCLouvain, Belgium) focused
on monocarboxylate transporter 1 (MCT1), a proton/lactate
cotransporter, that could contribute to the metastatic process
and, therefore, constitutes an interesting target for metastatic
prevention. He reported that MCT1 activates transcription factor
NF-κB, which promotes cancer cell migration independently
of MCT1 activity as a transporter. Unlike MCT1 activity
inhibition, the downregulation of MCT1 expression inhibited
migration, invasion and spontaneous metastasis in vivo. Paolo
Ceppi (Uniklinikum Erlangen, Germany) then explained how
glucose metabolism controls the epithelial-to-mesenchymal
transition (EMT), a de-differentiation process used by cancer
cells to acquire invasive and resistance properties. He identified
that enzymes belonging to the polyol pathway (PP), aldo-
keto reductase family 1 member B1 (AKR1B1), and sorbitol
dehydrogenase, promote EMT and cell growth. The expression of
these enzymes was correlated with poor patient survival. Bárbara
Sousa (University of Porto, Portugal) described the control of
breast cancer metabolism by the cell-cell adhesion molecule P-
cadherin. She demonstrated that P-cadherin promotes glycolysis
and reduces oxidative stress, suggesting an important role in
anoikis resistance and metastasis. Altogether, these insights
illustrated the crucial role of metabolic plasticity in cancer
metastasis providing new opportunities of targeting.
TUMOR HETEROGENEITY AND
METABOLIC CROSSTALKS
Tumors are known to be highly glycolytic, with lactate
concentrations up to 40mM in the tumor microenvironment.
Hence, tumor metabolism is often considered as a homogeneous
entity, with tumor relying only on aerobic glycolysis to survive
and grow. This view is outdated as we are progressively
acknowledging the impact of tumor heterogeneity on shaping
metabolic fluxes. In particular, we are beginning to elucidate the
network of “social” interaction between tumor cell populations,
ranging from metabolic symbiosis to metabolic competition,
based on the metabolic requirements of the ongoing biological
activities and nutrient availability. The session dedicated to
this topic provided several interesting points of discussion
concerning tumor heterogeneity and metabolic crosstalks. For
instance, Maria Yuneva (Francis Crick Institute, UK) discussed
her work on metabolic reprogramming controlled by the MYC
oncogene, highlighting the metabolic flexibility of tumors
and defining potential vulnerabilities. Then, Maria Shoshan
(Karolinska Institute, Sweden) presented her data investigating
the impact of metabolic flexibility on cisplatin resistance. On
a similar topic, the work of Giuseppe Taurino (University
of Parma, Italy) concerned the importance of amino acid
transport and stromal cooperation in counteracting nutritional
stress in asparaginase-treated acute lymphoblastic anemia,
thus evidencing the importance of such metabolic crosstalk in
supporting cancer fitness. Tumor metabolic heterogeneity is
not only shaped by cellular and biological heterogeneity, but
it is also promoted by nutrient availability due to inefficient
perfusion. To model this, Angela Otto (Technical University of
Munich, Germany) presented her work concerning metabolic
reprogramming under nutrient (glucose and glutamine)
limitation in vitro. A major issue in assessing tumor metabolic
heterogeneity is the limiting availability of tools to image
metabolism in vivo. The talk of Valery Khramtsov (West
Virginia University, USA) focused on the use of low-field
electron paramagnetic resonance (EPR)-based techniques, in
combination with specially designed functional paramagnetic
probes, to measure various parameters such as oxygenation,
pH, and inorganic phosphate availability, providing interesting
observations on the correlation of specific nutrient availability
with tumor aggressiveness.
TUMOR ACIDOSIS AND METABOLIC
ADAPTATIONS
This session was focused on intratumoral acidosis and its effect
on cancer biology. Extracellular acidosis is mainly due to an
enhancement of tumor-associated glycolytic activity also in
conditions of normal oxygen supply (Warburg effect), and it
is now considered to be a hallmark of cancer. As described by
Dario Longo (University of Turin, Italy), it is currently possible to
directly measure in vivo the intratumoral pH by usingMRI-based
approaches. This innovative technology will be crucial tomeasure
intratumoral pH in real-time, both for diagnostic and prognostic
purpose, as well as for the monitoring of treatment response,
like for the evaluation of the cytotoxic effect of anticancer drugs
that target proton pumps/transporters. Among these drugs, one
example has been proposed by Ivana Novak (University of
Copenhagen, Denmark) in pancreatic cancer that expresses both
gastric and non-gastric H+/K+- ATPases. In this tumor type,
H+/K+- ATPases contribute to secretin-stimulated secretion
and participate in intracellular pH regulation. Their inhibition
by using either proton pump inhibitors (PPI) or potassium-
competitive blockers reduced tumor growth and dissemination.
Similarly, as discussed by Stine Falsig Pedersen (University
of Copenhagen, Denmark) in luminal breast carcinoma cells,
targeting the Na+/H+ exchanger NHE1 and the Na+/HCO−3
cotransporter NBCn1 delayed cell cycle progression in different
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ways, including the expression and phosphorylation of cell
cycle regulatory proteins, with NHE1 mainly involved in the S
phase and NBC1 in the G2/M phase. Karin Bartel (Ludwing-
Maximilians-University of Munich, Germany) showed that, in
addition to altering pH homeostasis, targeting proton/ion pumps
and transporters might have an indirect effect on cancer cell
metabolism. Indeed, inhibition of V-ATPase, a crucial regulator
of lysosome acidification, produced a change in triacylglycerol
distribution and composition, a different morphology in lipid
droplets, and impaired mitochondrial functions. Also, MCTs
regulate tumor metabolic alterations. As reported by Fatima
Baltazar (University of Braga, Portugal), glioblastoma cells are
forced to adopt a glycolytic phenotype in hypoxic tumor regions,
with the production of high levels of both protons and lactate.
In these cells, MCT1 targeting decreased glycolytic metabolism,
cell migration, and invasion and induced cell death. Furthermore,
as mentioned by Cyril Corbet (UCLouvain, Belgium), when
coupled with the inhibition of mitochondrial pyruvate carrier,
MCT1 targeting is even more cytotoxic and can be suggested
for radiosensitization.
CANCER METABOLISM AND IMMUNE
RESPONSES
Interactions between cancer cells and their microenvironment
are now recognized as major players in tumorigenesis, tumor
growth, and shaping the evolutionary path of many if not
all cancers. A large fraction of tumors display infiltration
by immune cells, and intense research has been initiated to
deconvolute the role of the immune system in the process.
These interactions are, however, not unique to tumors, and
insights in cancer metabolism and immune responses can be
achieved by studying other in vivo processes where immune
cells determine the fate of growing or regenerating tissues. In
the opening talk, Massimiliano Mazzone (KULeuven, Belgium)
showed intriguing data on how macrophages and skeletal
muscle satellite cells compete for glutamine in the tissue
environment. He provided evidence for this competition by
showing that genetic deletion and pharmacologic targeting of
glutamate dehydrogenase 1 (GLUD1) in macrophages leads
to the rerouting of glutamate to glutamine synthesis and
secretion supported by glutaminase 1 (GLS1) upregulation,
which in turn sustains satellite cell activation, proliferation and
differentiation, altogether accelerating muscle regeneration and
functional recovery. In the following talks, two tumor-specific
examples of metabolic pathways participating in immune-cancer
cell crosstalk were presented by Stefano Biffo (University of
Milan, Italy) and Maša Ždralevic´ (Université Côte d’Azur,
France and Centre Scientifique de Monaco, Monaco). First,
Stefano Biffo has shown that a unique translational control
of lipid synthesis enzymes (including ACC1) via eIF6 and
eIF4E, operates in both cancer cells and immune responses,
providing a potential adaptive framework for tumor evolution.
Maša Ždralevic´ presented further details on the mechanism
of lactate secretion by cancer cells using cellular models
with LDH-A/B depletion. She showed that knockout of both
enzymes leads to re-activation of OXPHOS, which is sufficient
to maintain tumor growth and renders tumor cells uniquely
sensitive to OXPHOS inhibition. This raises the possibility
that the primary role of lactate production by cancer cells
is to provide signals to the tumor environment, including
immune cells, as previously suggested. The closing talk by
Mikhail M. Dikov (Ohio State University Medical Center,
USA) reported exciting technological advances to assess these
signals by profiling the tumor and lymph node metabolic
microenvironment using EPR spectroscopy with a newly
generated set of paramagnetic probes.
METABOLIC TARGETS IN CANCER
THERAPY
Acquired treatment resistance is a predominant cause of
treatment failure and death of cancer patients. Recent
investigations showed that acquired resistance often reflects
metabolic pathway rewiring. This session focused on novel
treatment schemes co-targeting metabolic pathways upregulated
as a consequence of treatment or tumor microenvironment
conditions. Miguel Quintela-Fandino (CNIO, Spain)
presented results from transcriptomic, phosphoproteomic
and metabolomics studies exploring the combination of
anti-angiogenic treatments with inhibitors of mitochondrial
respiration in mouse models of lung and breast cancers.
The group showed that small molecule anti-angiogenics led
to vascular normalization associated with a metabolic shift
toward OXPHOS, and that combination with e.g., metformin
could induce metabolic synthetic lethality. On the other hand,
monoclonal antibody anti-angiogenics exacerbated blood-vessel
abnormality and hypoxia. This was associated with upregulation
of a tumor-immune-suppressive phenotype, rendering such
treatment synergistic with e.g., anti-PD-L1 treatment. Steven
Hurstings (University of North Carolina, USA) combined
a calorie restriction-mimetic diet (CR) with inhibition of
autophagy, which is upregulated as a consequence of CR.
Cell culture, as well as in vivo studies of pancreatic ductal
adenocarcinoma (PDAC), revealed that growth-suppressive
effects of CR in the form of rapamycin or IGF-1R/insulin
receptor inhibition were strongly potentiated by co-treatment
with chloroquine-related compounds to inhibit autophagy.
There is, however, a serious lack of specific anti-autophagy
treatments suitable for clinical use. Following up on this
theme, Angelo de Milito (Sprint Bioscience, Sweden) presented
data on the development and efficacy of inhibitors of class
III phosphatidyl-3-kinase Vps34. Vps34 inhibition would be
particularly powerful in combination with treatment schemes
that elicit upregulation of autophagy. The team found that
cytotoxicity of receptor tyrosine kinase inhibitors Sunitinib and
Erlotinib in breast cancer cell lines was potentiated by Vps34,
consistent with upregulation of autophagy by these treatments.
Finally, Margherita Cortini (Rizzoli Orthopedic Institute, Italy)
enlightened the crucial role of lipid metabolism in determining
the aggressiveness of osteosarcoma in response to extracellular
acidosis, with particular regard to the sphingolipid pathway.
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CONCLUSION
The somatic evolution of cancers leading to their invasive
behaviors includes metabolic rewiring that endows cancer cells
with the ability to survive and proliferate in a highly selective
microenvironment of hypoxia, acidosis, and severe nutrient
restriction. Over manymonths or years in this environment, cells
emerge with more adaptable, aggressive and de-differentiated
phenotypes. An important component of such phenotypes is
aerobic glycolysis, known as Warburg effect. In the closing
lecture, Robert J. Gillies (Moffitt Cancer Center, Tampa, USA)
discussed the nature of the microenvironmental conditions
and mechanisms that select for the glycolytic phenotype,
highlighting work using an approach based on exposure of non-
metastatic/non-glycolytic cancer cells to microenvironmental
selection including acidity, hypoxia and low glucose followed
by regrowth in normal conditions. Resulting clones exhibited
increased rates of aerobic glycolysis and upregulation of a
number of cancer-related genes. This approach explains why and
how cells acquire a glycolytic phenotype in early cancers, which
is a hallmark of aggressiveness and poor outcome.
ISCaM aims to promote interactions between basic and
clinical researchers and between young and senior scientists,
which was facilitated by the international composition of
the meeting (80 attendees representing 14 countries), vivid
discussions in the audience and beyond, and social activities.
Oral and poster communications were demonstrated in sessions
focusing on emerging aspects of cancer metabolism that were
co-chaired by a principal and by a young investigator. Three
young investigators (Jessica Whitburn, Preeta Anathanarayanan,
and Sepideh Aminzadeh-Gohari) received travel grants from the
Local Organizers. Prizes were awarded to young investigators
who delivered best scientific presentations: the first ISCaM
award for best oral presentation went to Elisabeth Wyart
(her topic is highlighted above) and the second ISCaM award
for the best poster presentation went to Joao Santiago de
Jesus (UCLouvain, Belgium) for his study of acidosis-induced
lipid metabolism in cancer invasiveness. In line with ISCaM’s
objective to improve the outcome of cancer patients through
the discovery and development of new anticancer drugs, several
potential anticancer strategies related to tumor metabolism
were presented.
Conclusively, ISCaM2018 provided the audience with most
recent discoveries on metabolic adaptations and targets in
cancer. The follow up discussions will be held at the 6th
annual ISCaM2019 meeting in Braga, Portugal, 19–21 October
2019, entitled “Cancer Metabolic Rewiring: Mapping the
Road to Clinical Translations” (https://www.iscams.org/meeting/
iscam2019-6th-annual-meeting-braga).
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